Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF-EMF) Therapy - (0581)

Cigna considers intrabuccal/systemic amplitude‑modulated radiofrequency electromagnetic fields therapy (HCPCS E0767) experimental, investigational, and unproven and therefore not covered—while the TheraBionic P1 has an FDA HDE for advanced HCC, this policy does not establish coverage and AutEMdev is not FDA‑approved. Claims must use appropriate covered diagnosis/procedure codes and comply with the applicable benefit plan terms (otherwise they will be denied); reimbursement is not allowed for conditions or services not covered by the policy and coverage is subject to plan-specific terms and medical director review.

"None. Amplitude-modulated, radiofrequency electromagnetic fields therapy (HCPCS E0767) is considered experimental, investigational or unproven (Coverage Policy)."

Sign up to see full coverage criteria, indications, and limitations.